Viatris Inc
Viatris Inc. is a U.S.-based global pharmaceutical company that develops, manufactures, and distributes branded medicines, generic medicines, and complex products. Its business is organized across Developed Markets, Greater China, JANZ, and Emerging Markets, with operations spanning more than 165 countries and territories.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEstablished prescription brands sold in developed and emerging markets.
Off-patent medicines, including complex generics and first-to-file launches.
Harder-to-make products such as inhalers, injectables, and other complex dosage forms.
Localized branded and generic medicines sold across developing markets and Asia.
Customers
Viatris sells primarily into the pharmaceutical distribution chain, including wholesalers, retail drug chains, pharmacies, governments, institutions, physicians, and managed care-related buyers. In some markets it also serves public health systems and other institutional customers that buy medicines for broad patient access.
Buy large volumes of prescription medicines for downstream pharmacy distribution and price-sensitive access.
Purchase medicines for public health systems, hospitals, and reimbursement programs.
Stock branded and generic products for retail dispensing and patient access.
Influence demand for branded, specialty, and complex medicines through prescribing choices.
Negotiate access, rebates, and formulary placement that affect product uptake.
Strategy
Viatris’ strategy centers on using its global scale, broad portfolio, and supply chain to serve patients across many markets and therapeutic areas. The company is also focused on modernizing its technology, data, and talent capabilities while advancing new product launches and selected innovative assets.
New products help offset lifecycle pressure on older medicines and broaden market coverage.
Innovative and first-to-market programs can create differentiated growth opportunities.
Consistent manufacturing and distribution are essential in regulated pharmaceutical markets.
Better data, systems, and talent support execution across a complex global footprint.
Geography
2025Viatris is headquartered in the United States and operates through four geographic segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Developed Markets covers North America and Europe, while Emerging Markets spans more than 125 countries across Asia, Africa, Eastern Europe, Latin America, and the Middle East.
Share of the revenue the company reports by geography.
Risks
Viatris faces pricing pressure, customer concentration, regulatory scrutiny, and litigation risk typical of large pharmaceutical distributors and manufacturers. Its global footprint also exposes it to foreign exchange, trade restrictions, supply chain disruption, and country-specific reimbursement or pricing controls.
- Pricing and reimbursement pressureImpact: HighLikelihood: High
Wholesalers, retail chains, and managed care organizations have increasing bargaining power, which can compress realized prices and rebates.
Exposure - Customer concentrationImpact: HighLikelihood: Medium
A limited number of large customers account for a meaningful share of sales, so lost business would materially affect revenue and cash flow.
Exposure: Top three customers represented about 25% of net sales in 2025
- Patent and intellectual property litigationImpact: HighLikelihood: Medium
Generic and complex-generic launches can trigger infringement claims and delay commercialization.
Exposure: At-risk launches and first-to-file opportunities
- Regulatory and compliance riskImpact: HighLikelihood: Medium
Pharmaceutical products are heavily regulated, and violations can lead to delays, penalties, or product restrictions.
Exposure - Foreign exchange and international exposureImpact: MediumLikelihood: Medium
Revenue and costs are spread across many currencies and jurisdictions, creating translation and transaction risk.
Exposure: More than 165 countries and territories
Accounting
Judgemental itemsPharmaceutical net sales are recorded after rebates, chargebacks, returns, and other allowances, so estimates can move revenue materially.
Impact: Net sales and receivables
The company carries significant acquired intangibles and goodwill, which require periodic impairment testing.
Impact: Operating income and equity
Purchase accounting affects cost of sales, EBITDA, and earnings through amortization and remeasurement items.
Impact: Adjusted and reported earnings
Ongoing litigation and government inquiries require judgment in accruals and disclosures.
Impact: Expenses and liabilities
Global operations and restructuring of legal entities create judgment in tax provisions and deferred taxes.
Impact: Tax expense and cash taxes
Similar listed companies
Publicly listed companies with a comparable business focus.
Elite Pharmaceuticals Inc /NV/
ELTP · Pharmaceutical Preparations
Elite Pharmaceuticals, Inc.
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Novartis AG
NVS · Pharmaceutical Preparations
Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas.
GoodRx Holdings, Inc.
GDRX · Services-Computer Processing & Data Preparation
MIRA Pharmaceuticals, Inc
MIRA · Pharmaceutical Preparations
Eli Lilly and Company
LLY · Pharmaceutical Preparations
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products, with a portfolio anchored by diabetes, obesity, oncology, immunology, and neuroscience medicines.
Last updated: 24/09/2026